The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends

David Thomas, BIO’s Senior Vice President of Industry Analysis, will provide an overview of recent investment and deal trends for emerging therapeutic companies, as well as an update on the R&D pipeline and recent FDA approvals. The BIO Industry Analysis team publishes quarterly interactive data on licensing, M&A, venture capital, IPOs, follow-on public offerings, and FDA approvals at www.bio.org/iareports.